GO
Loading...

Enter multiple symbols separated by commas

Stocks AstraZeneca PLC

More

  • July 20- Bristol-Myers Squibb Co said a late-stage trial of its drug, Opdivo, was stopped early after the immunotherapy was found to be effective in patients with the most common form of kidney cancer. The drug competes with Merck& Co's Keytruda. AstraZeneca Plc, Pfizer Inc and other drugmakers are also developing PD-1 inhibitors, or similar drugs known as PD-L1...

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...

  • *Paulson expected to put pressure on Syngenta board. July 15- Hedge fund Paulson& Co has taken a stake in Syngenta AG and could push for the Swiss pesticide maker's board to accept a takeover offer from U.S. seed company Monsanto Co, people familiar with the matter said. Monsanto, the world's largest seed company, has made a $45 billion bid for Syngenta that the Swiss...

  • July 14- Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics...

  • July 13- The U.S. Food and Drug Administration approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The FDA said on Tuesday the approval was based on results from a trial of 106 patients with previously untreated non-small cell lung cancer. The National Cancer Institute estimates more than 158,000 will die from the...

  • July 13- The U.S. Food and Drug Administration has approved AstraZeneca Plc's drug, Iressa, as a first-line treatment for a common form of lung cancer. The drug was previously approved for use in non-small cell lung cancer patients only after they did not respond to chemotherapy. The FDA said on Tuesday the approval was based on results from a trial of 106 patients...

  • Early movers: PEP, AA, WBA, AVP, LB, AZN, MA & more Thursday, 9 Jul 2015 | 7:58 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • AstraZeneca divests gastrointestinal drug for $215 mln Thursday, 9 Jul 2015 | 3:07 AM ET

    LONDON, July 9- AstraZeneca struck a further "externalisation" deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million. The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer,...

  • Celgene places $1B bet on Juno Therapeutics Tuesday, 30 Jun 2015 | 1:45 AM ET

    Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.

  • June 22- The U.S. Food and Drug Administration on Monday approved Medicines Co's blood clot preventer Cangrelor, which has faced multiple setbacks since it first entered late-stage studies close to a decade back. Medicines Co has funneled about $200 million into developing Cangrelor over the past decade, which included two unsuccessful trials and a pivotal...

  • Shares of the company, whose customers include AstraZeneca Plc, General Electric Co and Chevron Corp, rose about 8 percent in extended trading on Wednesday. Box raised its full-year forecast to $286 million- $290 million from $281 million- $285 million earlier. The company's main competitors include privately held Dropbox, Microsoft Corp's OneDrive, Citrix...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. A spokeswoman said on Wednesday Morrison was departing to become chief executive of an unlisted venture capital-backed drugmaker in the United States,...

  • LONDON, June 10- AstraZeneca's chief medical officer and head of global late-stage drug development Briggs Morrison is to leave the company, creating a gap at the top of the group's research operations. Morrison, who joined AstraZeneca from Pfizer in 2012, has played a central role in the British drugmaker's bid to turn around its portfolio.

  • M&A: Dealmaking like 2007 all over again? Wednesday, 3 Jun 2015 | 7:29 AM ET

    Mergers and acquisitions are close to pre-financial crisis levels for the first time in 2015, as companies search for deals again.

  • June 2- AstraZeneca Plc would consider acquiring a developer of a new type of cancer therapy aimed at supercharging the body's immune response, Bloomberg quoted Chief Executive Pascal Soriot as saying on Tuesday. An earlier version of the Bloomberg article quoted Soriot as saying that AstraZeneca would consider buying a company such as Juno Therapeutics...

  • *Dollar drops on optimism of Greece deal with creditors. *Intel drops after rating cut; biggest drag on indexes. June 2- U.S. stocks erased earlier losses to turned positive on Tuesday afternoon on optimism that Greece would strike a deal with its creditors, while weak U.S. data and bearish comments from a Federal Reserve board member allayed fears of a near-term...

  • *Juno jumps on report of AstraZeneca interest. June 2- U.S. stocks were lower in late morning trading, paring some of their losses earlier in the session, as weak factory orders data and bearish comments from a Federal Reserve board member allayed fears of a rate hike coming sooner rather than later. "Interest rates are not going to matter if they're rising because of...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. AstraZeneca and Juno already have a collaboration agreement to test one of AstraZeneca's cancer drugs in combination with Juno's CAR-T cell therapy, which is considered to be a breakthrough in...

  • June 2- AstraZeneca Plc would consider buying a company such as Juno Therapeutics Inc, Bloomberg reported AstraZeneca's CEO as saying, according to StreetInsider. The companies were not immediately available to comment. Juno is one among the few companies that are developing a new class of immuno-oncology treatments called CAR-T cell therapies.

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...